Fluconazole serum concentrations and pharmacokinetics in an obese patient

Louise Glassner Cohen, Alan DiBiasio, Steven J. Lisco, William E. Hurford

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Current fluconazole dosing recommendations are based on pharmacokinetic parameters calculated from serum concentration data in subjects and patients of normal weight. These recommendations may be inaccurate when applied to obese individuals due to the physiologic changes of obesity that may influence drug pharmacokinetics: A 39-year-old morbidly obese man (BMI 48.3 kg/m2) was treated with fluconazole 1200 mg/day infused over 6 hours. After 14 days of therapy, blood samples were obtained at 0, 1, 2, 4, 8, 12, 18, and 24 hours after infusion and steady-state serum concentrations were determined using a bioassay. Pharmacokinetic parameters calculated were area under the concentration-time curve (AUC0-24) 574.9 mg/L·hour, average steady- state serum concentration 23.9 mg/L, and fluconazole clearance 139.4 ml/minute. Compared with published data, our patient had a lower area under the curve and increased fluconazole clearance. These changes may be due to the drugs increased volume of distribution. Based on these data and the favorable toxicity profile of fluconazole, we recommend considering higher dosages in such morbidly obese patients.

Original languageEnglish (US)
Pages (from-to)1023-1026
Number of pages4
JournalPharmacotherapy
Volume17
Issue number5 I
StatePublished - Sep 1 1997

Fingerprint

Fluconazole
Pharmacokinetics
Serum
Biological Assay
Pharmaceutical Preparations
Area Under Curve
Obesity
Weights and Measures

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Cohen, L. G., DiBiasio, A., Lisco, S. J., & Hurford, W. E. (1997). Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy, 17(5 I), 1023-1026.

Fluconazole serum concentrations and pharmacokinetics in an obese patient. / Cohen, Louise Glassner; DiBiasio, Alan; Lisco, Steven J.; Hurford, William E.

In: Pharmacotherapy, Vol. 17, No. 5 I, 01.09.1997, p. 1023-1026.

Research output: Contribution to journalArticle

Cohen, LG, DiBiasio, A, Lisco, SJ & Hurford, WE 1997, 'Fluconazole serum concentrations and pharmacokinetics in an obese patient', Pharmacotherapy, vol. 17, no. 5 I, pp. 1023-1026.
Cohen LG, DiBiasio A, Lisco SJ, Hurford WE. Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy. 1997 Sep 1;17(5 I):1023-1026.
Cohen, Louise Glassner ; DiBiasio, Alan ; Lisco, Steven J. ; Hurford, William E. / Fluconazole serum concentrations and pharmacokinetics in an obese patient. In: Pharmacotherapy. 1997 ; Vol. 17, No. 5 I. pp. 1023-1026.
@article{9e6c50274b474288a17df78abb7a17b5,
title = "Fluconazole serum concentrations and pharmacokinetics in an obese patient",
abstract = "Current fluconazole dosing recommendations are based on pharmacokinetic parameters calculated from serum concentration data in subjects and patients of normal weight. These recommendations may be inaccurate when applied to obese individuals due to the physiologic changes of obesity that may influence drug pharmacokinetics: A 39-year-old morbidly obese man (BMI 48.3 kg/m2) was treated with fluconazole 1200 mg/day infused over 6 hours. After 14 days of therapy, blood samples were obtained at 0, 1, 2, 4, 8, 12, 18, and 24 hours after infusion and steady-state serum concentrations were determined using a bioassay. Pharmacokinetic parameters calculated were area under the concentration-time curve (AUC0-24) 574.9 mg/L·hour, average steady- state serum concentration 23.9 mg/L, and fluconazole clearance 139.4 ml/minute. Compared with published data, our patient had a lower area under the curve and increased fluconazole clearance. These changes may be due to the drugs increased volume of distribution. Based on these data and the favorable toxicity profile of fluconazole, we recommend considering higher dosages in such morbidly obese patients.",
author = "Cohen, {Louise Glassner} and Alan DiBiasio and Lisco, {Steven J.} and Hurford, {William E.}",
year = "1997",
month = "9",
day = "1",
language = "English (US)",
volume = "17",
pages = "1023--1026",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5 I",

}

TY - JOUR

T1 - Fluconazole serum concentrations and pharmacokinetics in an obese patient

AU - Cohen, Louise Glassner

AU - DiBiasio, Alan

AU - Lisco, Steven J.

AU - Hurford, William E.

PY - 1997/9/1

Y1 - 1997/9/1

N2 - Current fluconazole dosing recommendations are based on pharmacokinetic parameters calculated from serum concentration data in subjects and patients of normal weight. These recommendations may be inaccurate when applied to obese individuals due to the physiologic changes of obesity that may influence drug pharmacokinetics: A 39-year-old morbidly obese man (BMI 48.3 kg/m2) was treated with fluconazole 1200 mg/day infused over 6 hours. After 14 days of therapy, blood samples were obtained at 0, 1, 2, 4, 8, 12, 18, and 24 hours after infusion and steady-state serum concentrations were determined using a bioassay. Pharmacokinetic parameters calculated were area under the concentration-time curve (AUC0-24) 574.9 mg/L·hour, average steady- state serum concentration 23.9 mg/L, and fluconazole clearance 139.4 ml/minute. Compared with published data, our patient had a lower area under the curve and increased fluconazole clearance. These changes may be due to the drugs increased volume of distribution. Based on these data and the favorable toxicity profile of fluconazole, we recommend considering higher dosages in such morbidly obese patients.

AB - Current fluconazole dosing recommendations are based on pharmacokinetic parameters calculated from serum concentration data in subjects and patients of normal weight. These recommendations may be inaccurate when applied to obese individuals due to the physiologic changes of obesity that may influence drug pharmacokinetics: A 39-year-old morbidly obese man (BMI 48.3 kg/m2) was treated with fluconazole 1200 mg/day infused over 6 hours. After 14 days of therapy, blood samples were obtained at 0, 1, 2, 4, 8, 12, 18, and 24 hours after infusion and steady-state serum concentrations were determined using a bioassay. Pharmacokinetic parameters calculated were area under the concentration-time curve (AUC0-24) 574.9 mg/L·hour, average steady- state serum concentration 23.9 mg/L, and fluconazole clearance 139.4 ml/minute. Compared with published data, our patient had a lower area under the curve and increased fluconazole clearance. These changes may be due to the drugs increased volume of distribution. Based on these data and the favorable toxicity profile of fluconazole, we recommend considering higher dosages in such morbidly obese patients.

UR - http://www.scopus.com/inward/record.url?scp=0030770456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030770456&partnerID=8YFLogxK

M3 - Article

C2 - 9324192

AN - SCOPUS:0030770456

VL - 17

SP - 1023

EP - 1026

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5 I

ER -